Evolving Immunotherapy Approaches for Renal Cell Carcinoma

被引：24

作者：

Curtis, Susanna A. ^{[1
]}

Cohen, Justine V. ^{[1
]}

Kluger, Harriet M. ^{[1
]}

机构：

[1] Yale Canc Ctr, Dept Med, Sect Med Oncol, 333 Cedar St,POB 208028, New Haven, CT 06510 USA

来源：

CURRENT ONCOLOGY REPORTS | 2016年 / 18卷 / 09期

关键词：

Renal cell carcinoma; Immunotherapy; Cytokines; Adoptive cell therapy; Vaccine therapy; Immune checkpoint inhibitors; TUMOR-INFILTRATING LYMPHOCYTES; ACTIVATED KILLER-CELLS; HIGH-DOSE INTERLEUKIN-2; PLUS INTERFERON-ALPHA; PHASE-III TRIAL; RECOMBINANT INTERLEUKIN-2; DENDRITIC CELLS; ANTI-PD-L1; ANTIBODY; RADICAL NEPHRECTOMY; RANDOMIZED-TRIAL;

D O I：

10.1007/s11912-016-0542-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usually not durable. Modulating the immune system with cytokine therapy, vaccine therapy, cell therapy, and checkpoint inhibitors offers hope of prolonged survival. Standard and emerging immune therapy approaches and combinations of immune therapies and other modalities are reviewed.

引用

页数：9

共 79 条

[1] Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study [J].

Amato, Robert J. ;

Hawkins, Robert E. ;

Kaufman, Howard L. ;

Thompson, John A. ;

Tomczak, Piotr ;

Szczylik, Cezary ;

McDonald, Mike ;

Eastty, Sarah ;

Shingler, William H. ;

de Belin, Jackie ;

Goonewardena, Madusha ;

Naylor, Stuart ;

Harrop, Richard .

CLINICAL CANCER RESEARCH, 2010, 16 (22) :5539-5547

[2] Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results [J].

Amin, Asim ;

Dudek, Arkadiusz Z. ;

Logan, Theodore F. ;

Lance, Raymond S. ;

Holzbeierlein, Jeffrey M. ;

Knox, Jennifer J. ;

Master, Viraj A. ;

Pal, Sumanta K. ;

Miller, Wilson H., Jr. ;

Karsh, Lawrence I. ;

Tcherepanova, Irina Y. ;

DeBenedette, Mark A. ;

Williams, W. Lee ;

Plessinger, Douglas C. ;

Nicolette, Charles A. ;

Figlin, Robert A. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3

[3]

[Anonymous], 2016, J CLIN ONCOL, DOI DOI 10.1200/JCO.2016.34.2_SUPPL.559

[4] Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. [J].

Atkins, Michael B. ;

Choueiri, Toni K. ;

Hodi, F. Stephen ;

Thompson, John A. ;

Hwu, Wen-Jen ;

McDermott, David F. ;

Brookes, Melissa ;

Tosolini, Alessandra ;

Ebbinghaus, Scot ;

Yang, Zijiang ;

Gause, Christine K. ;

Perini, Rodolfo F. ;

Ribas, Antoni .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[5] Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens [J].

Baine, Marina K. ;

Turcu, Gabriela ;

Zito, Christopher R. ;

Adeniran, Adebowale J. ;

Camp, Robert L. ;

Chen, Lieping ;

Kluger, Harriet M. ;

Jilaveanu, Lucia B. .

ONCOTARGET, 2015, 6 (28) :24990-25002

[6] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[7] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[8]

BUKOWSKI RM, 1991, CANCER RES, V51, P4199

[9] Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response [J].

Calderhead, David M. ;

DeBenedette, Mark A. ;

Ketteringham, Helen ;

Gamble, Alicia H. ;

Horvatinovich, Joe M. ;

Tcherepanova, Irina Y. ;

Nicolette, Charles A. ;

Healey, Don G. .

JOURNAL OF IMMUNOTHERAPY, 2008, 31 (08) :731-741

[10]

Callea M, 2014, ASCO M, V32, P4585, DOI [DOI 10.1200/JCO.2014.32.15_SUPPL.4585, 10.1200/jco.2014.32.15_suppl.4585]

← 1 2 3 4 5 6 7 8 →